Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Suk Bae | - |
dc.contributor.author | Song, Il Han | - |
dc.contributor.author | Kim, Young Min | - |
dc.contributor.author | Noh, Ran | - |
dc.contributor.author | Kang, Ha Yan | - |
dc.contributor.author | Lee, Hyang Ie | - |
dc.contributor.author | Yang, Hyeon Yoong | - |
dc.contributor.author | Kim, An Na | - |
dc.contributor.author | Chae, Hee Bok | - |
dc.contributor.author | Lee, Sae Hwan | - |
dc.contributor.author | Kim, Hong Soo | - |
dc.contributor.author | Lee, Tae Hee | - |
dc.contributor.author | Kang, Young Woo | - |
dc.contributor.author | Lee, Eaum Seok | - |
dc.contributor.author | Kim, Seok Hyun | - |
dc.contributor.author | Lee, Byung Seok | - |
dc.contributor.author | Lee, Heon Young | - |
dc.date.accessioned | 2021-08-12T02:25:31Z | - |
dc.date.available | 2021-08-12T02:25:31Z | - |
dc.date.issued | 2012-12-21 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.issn | 2219-2840 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14590 | - |
dc.description.abstract | AIM: To evaluate the treatment outcomes of clevudine compared with entecavir in antiviral-naive patients with chronic hepatitis B (CHB). METHODS: We retrospectively analyzed the clinical data of CHB patients treated with clevudine 30 mg/d and compared their clinical outcomes with patients treated with entecavir 0.5 mg/d. The biochemical response, as assessed by serum alanine aminotransferase (ALT) activity, virologic response, as assessed by serum hepatitis B virus DNA (HBV DNA) titer, serologic response, as assessed by hepatitis B e antigen (HBeAg) status, and virologic breakthrough with genotypic mutations were assessed. RESULTS: Two-hundred and fifty-four patients [clevudine (n = 118) vs entecavir (n = 136)] were enrolled. In clevudine-treated patients, the cumulative rates of serum ALT normalization were 83.9% at week 48 and 91.5% at week 96 (80.9% and 91.2% in the entecavir group, respectively), the mean titer changes in serum HBV DNA were -6.03 and -6.55 log(10) copies/mL (-6.35 and -6.86 log(10) copies/mL, respectively, in the entecavir group), and the cumulative non-detection rates of serum HBV DNA were 72.6% and 83.1% (74.4% and 83.8%, respectively, in the entecavir group). These results were similar to those of entecavir-treated patients. The cumulative rates of HBeAg seroconversion were 21.8% at week 48 and 25.0% at week 96 in patients treated with clevudine, which was similar to patients treated with entecavir (22.8% and 27.7%, respectively). The virologic breakthrough in the clevudine group occurred in 9 (7.6%) patients at weeks 48 and 15 (12.7%) patients at week 96, which primarily corresponded to genotypic mutations of rtM204I and/or rtL180M. There was no virologic breakthrough in the entecavir group. CONCLUSION: In antiviral-naive CHB patients, long-term treatment outcomes of clevudine were not inferior to those of entecavir, except for virologic breakthrough. (C) 2012 Baishideng. All rights reserved. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Baishideng Publishing Group | - |
dc.title | Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.3748/wjg.v18.i47.6943 | - |
dc.identifier.scopusid | 2-s2.0-84873922487 | - |
dc.identifier.wosid | 000313114100011 | - |
dc.identifier.bibliographicCitation | World Journal of Gastroenterology, v.18, no.47, pp 6943 - 6950 | - |
dc.citation.title | World Journal of Gastroenterology | - |
dc.citation.volume | 18 | - |
dc.citation.number | 47 | - |
dc.citation.startPage | 6943 | - |
dc.citation.endPage | 6950 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | ENTECAVIR | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | POTENT | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Hepatitis B virus | - |
dc.subject.keywordAuthor | Clevudine | - |
dc.subject.keywordAuthor | Entecavir | - |
dc.subject.keywordAuthor | Treatment outcomes | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.